Purpose: Anatomical motion, both cyclical and aperiodic, can impact the dose delivered during external beam radiation. In this work, we evaluate the use of a research version of the clinical TomoTherapy â dose calculator to calculate dose with intrafraction rigid motion. We also evaluate the feasibility of a method of motion compensation for helical tomotherapy using the jaws and MLC. Methods: Treatment plans were created using the TomoTherapy treatment planning system. Dose was recalculated for several simple rigid motion traces including a 4 mm step motion applied either longitudinally or transversely, and a sinusoidal motion. The calculated dose volumes were compared to dose measurements that were performed by translating the phantom with the same motion traces used in the calculations. Measurements were made using film and ion chambers. Finally, the delivery plans were modified to compensate for the motion by sweeping the jaws for longitudinal motion and shifting the MLC leaves for transverse motion, and the calculations and measurements were repeated. Results: A transverse step motion shifted the dose that was delivered after the step occurred, but otherwise did not impact the dose distribution. Film measurements agreed with dose calculations to within 2%/2 mm for 99% of dose points within the 50% isodose line. A shift in the MLC leaf delivery pattern successfully compensated for the step motion to within the 3 mm accuracy allowed by the finite leaf widths. A longitudinal step motion impacted the dose in the interior of the target volume to a degree that was dependent on the planning field width and step size. Film measurements agreed with dose calculations to within 2%/2 mm for 98% of dose points within the 50% isodose line. Shifts in the jaw position successfully compensated for the longitudinal step motion. Sinusoidal (breathinglike) motion was also studied, with similar results. Conclusions: A research version of the clinical TomoTherapy dose calculator has been shown to accurately calculate the dose from treatment plans delivered in the presence of arbitrary rigid motion. Modifications to the delivery plan using jaw and MLC leaf shifts that follow the motion can successfully compensate for the target motion.
INTRODUCTION
Intrafractional patient motion can cause discrepancies between the dose distribution that is calculated during treatment planning and the delivered dose distribution. The motion may cause a dose blurring, where only the edges of the intended dose distribution are impacted, or there may be an interplay effect that can impact the interior volume of the intended dose. 1 Tomotherapy deliveries are somewhat unique compared to conventional C-arm linac deliveries due to the fast rotation speed, the binary MLC intensity modulation, and the continuous couch motion, and therefore the effects of motion on the delivered dose may be unique.
The impact of motion on tomotherapy deliveries has been previously studied. Some have been exclusively experimental studies. 2, 3 In several studies, dose calculators have been developed that calculate the dose along the axis of delivery and allow the introduction of superior-inferior (SI) motion. [4] [5] [6] [7] Tudor 8 describes a dose calculator that can calculate threedimensional dose volumes for tomotherapy delivery plans, but only includes SI motion. A Monte Carlo dose calculator has been described that generates fully three-dimensional dose calculations for tomotherapy delivery plans along with all aspects of motion including nonrigid motion. 9 However, the motion was assumed to be regular and reproducible, and other studies have found that irregular motion is an important factor in the resulting dose perturbation. 4, 7, 8 A research version of the commercial TomoTherapy treatment planning software has been previously used to study the effects of arbitrary rigid motion on the delivered dose. 10 This approach takes advantage of years of clinical validation of the commercial dose calculator, yields a three-dimensional dose volume, and allows both random and cyclic intrafraction motion to be studied. However, that previous work used an older version of the commercial dose calculator. Since that work was published, the TomoTherapy treatment planning software has been substantially updated to use a GPU-based dose calculation algorithm to improve the speed of calculations. 11, 12 The previous work also did not model new features of the TomoTherapy system that have since been released, including TomoEDGE TM dynamic-jaw deliveries. 13, 14 In this work, we used an updated version of the commercial TomoTherapy treatment planning software to calculate dose to targets with intrafraction rigid motion and with delivery plans employing dynamic-jaws. We evaluated the calculated dose by comparing with film measurements in phantoms that were translated with the same motion profile. We also investigated the feasibility of modifying the delivery plan via jaw motion and MLC leaf pattern shifts to compensate for the intrafraction motion, and we evaluated the dose calculation results for motion with and without compensation.
MATERIALS AND METHODS

2.A. Treatment planning
Treatment plans were created and optimized on a TomoTherapy H TM Series Planning Station version 2.0.1 (HiÁArt â PS version 5.0.1). The plans used CT images of two different phantoms. One of the phantoms, shown in Fig. 1(a) , was a 30 cm diameter cylindrical solid-water phantom, sometimes referred to as a cheese phantom. The other was a smaller 15 cm diameter cylindrical acrylic phantom, shown in Fig. 1(b) , which could be supported on our motion platform and moved transversely. The prescription dose was 2 Gy per fraction, and in the cheese phantom, this dose was prescribed to two identical cylindrical targets 6 cm in diameter and 6 cm in length. One of the cylindrical targets was centered in the phantom and the other off-axis, and the two targets were separated by a gap of 2 cm. In the smaller acrylic phantom, the dose was prescribed to a single cylindrical volume 4 cm in diameter and 6 cm in length. The treatment plans included a range of field sizes from 1 cm to 5 cm, jaw modes of static or dynamic, and a modulation factor upper limit of 1.6. The 1 cm and 2.5 cm field width plans in the cheese phantom were prescribed a pitch of 0.28, while the 5 cm field width plan was prescribed a pitch of 0.43. The acrylic phantom plan was prescribed a pitch of 0.287. Gantry periods were in the 12 s to 14 s range for all plans except the 1 cm field width cheese phantom plan which used a 23 s gantry period. The total beam-on time ranged from less than 2 min for the plan utilizing a 5 cm field width, to over 6 min for the 1 cm field width.
2.B. Dose calculations with intrafraction motion
A research version of the TomoTherapy clinical planning system was used to recompute dose with the addition of an arbitrary rigid motion trace. This is achieved by inserting additional instructions into the delivery plan. The delivery plan is a set of delivery instructions that describe the couch movement, gantry rotation, jaw positions, and MLC leaf patterns. In a normal clinical plan, the couch motion is modeled as a rigid motion along the IEC-Y axis with constant velocity. However, with our research version, the rigid motion can be an arbitrary positional trace. We use the IEC fixed coordinate system to describe the axes, where the IEC-Y axes is parallel to the axis of the TomoTherapy gantry.
The current version of the dose calculator, including the clinical planning system, calculates dose at three angles per projection, with 51 projections per rotation. Correspondingly, the input motion trace was sampled three times per projection and inserted into the delivery plan. Compared to the dose calculator described by Ngwa 10 where dose was calculated at only a single angle per projection, the current dose calculator yields better spatial accuracy and also enables improved temporal resolution for simulating intrafraction motion. For the majority of delivery plans used in this study with gantry periods of less than 14 s, the three samples per projection yields sample intervals of less than 0.092 s. For the 23 s gantry period plan, the time between samples was 0.150 s. For the motion traces studied here and for the majority of clinical motion traces, this time resolution should be sufficient to faithfully model the motion. the target motion. The jaw compensation is calculated by determining the jaw motion required to shift the treatment field at isocenter by a distance equal to the target's longitudinal motion. In Fig. 2(a) , an example sinusoidal target motion profile is shown along with a corresponding jaw compensation profile in Fig. 2(b) . The jaw positions for the original delivery plan are shown as the bold, dotted lines. The original plan used dynamic-jaws, which improves the dose conformality at the superior and inferior edges of the target compared to a fixed jaw aperture delivery. 13, 14 The jaws begin with an aperture corresponding to a 1 cm field width, open to a maximum width corresponding to a 5 cm field width, and close back down to 1 cm at the inferior edge of the treatment. To compensate for the SI target motion, a compensating sinusoidal motion is added to the originally planned jaw motion as shown by the solid lines in Fig. 2(b) .
2.C.2. MLC compensation
A similar calculation is performed to determine the required shift in the original MLC leaf pattern to compensate for transverse (IEC-X and Z) motion. The MLC leaf pattern is shifted by an amount that best matches the magnitude of the motion perpendicular to the source-to-axis vector. Since the TomoTherapy system's MLC leaves have a width of 6.25 mm projected to isocenter, the transverse shifts are discretized to 6.25 mm distances and the motion perpendicular to the source-to-axis vector must be greater than half of the leaf width (3.125 mm) before MLC compensation is effective. In Fig. 3(a) , a step motion profile is shown with a 4 mm transverse step occurring 30 s after the start of the delivery. Figure 3(b) shows the original planned MLC leaf pattern (sinogram) for the acrylic phantom delivery plan, yielding the dose shown in Fig. 1(b) . Since the target dose is cylindrical and centered on the gantry isocenter, the active set of leaves is constant in time and the sinogram lacks the usual sinusoidal shape. Figure 3 (c) shows the same sinogram modified to compensate for the transverse step motion. The step motion amplitude of 4 mm is just large enough to necessitate a one leaf shift for a limited range of gantry angles where the step is perpendicular to the source-to-axis vector, and the direction of the leaf shifts is also gantry angle dependent.
2.D. Measurements
2.D.1. Motion platform
The motion platform is a custom design with three orthogonal actuators (BiSlide, Velmex, Inc, Bloomfield, NY, USA) to move a platform along three axes with submillimeter accuracy. Figure 4 shows the motion platform supporting the 15 cm diameter acrylic phantom. Parts of the actuator arms are visible in box A on the left of the figure, while box B outlines the support platform and the acrylic phantom. The platform cannot support the cheese phantom. Instead, the cheese phantom is resting on a movable platform with ball-bearings and attached to the motion platform with C-clamps. This method of attachment was sufficient to move the cheese phantom in the longitudinal (IEC-Y) direction, but not in the transverse directions (IEC-X or IEC-Z). The motion platform could be triggered to start delivering a motion trace coincident with the start of the treatment delivery, enabling repeatable measurements across multiple runs and allowing the motion trace to be modeled in dose calculations.
2.D.2. Motion traces
The motion platform was programmed to move with two different motion traces: a 4 mm step move as shown in Fig. 3 (a) and a 6 mm peak-to-peak sinusoidal motion as shown in Fig. 2 (a). The step move was applied in the IEC-X direction using the acrylic phantom, and the same motion profile was applied in the IEC-Y direction using the cheese phantom. The steps were timed to occur approximately halfway through each delivery. The sinusoidal motion was applied only in the IEC-Y direction to the cheese phantom. The same motion traces used to drive the motion platform were also used as input to the motion dose calculations.
2.D.3. Dose measurements
Absolute point dose measurements were acquired with a Model A1SL ion chamber (Standard Imaging) and relative planar dose measurements were measured using EDR2 film (Carestream Health). Both the acrylic and cheese phantoms contained holes to insert an ion chamber, as well as a separation to allow film to be inserted between the two halves. The film zero was calibrated by measuring an unexposed film from the same batch of films used for measurements. The rest of the film calibration reused calibration results generated during earlier experiments with different film batches. The film results were linearly scaled to match the ion chamber measurements. This process yielded results accurate to within 2% for dose levels from 50% to 100% of the prescribed dose, which covered all the features of interest in the film, including dose perturbations due to motion. However, inaccuracies due to the reuse of the older film calibration may explain the larger than 2% dose differences at dose levels less than 50%. As these dose levels were not relevant to the investigation, the calibrations were deemed acceptable.
For each delivery plan, dose measurements were acquired in three scenarios. First, dose measurements were made with no motion. Second, a motion trace was executed by the motion platform and the dose measurements repeated. Finally, the motion trace was repeated and in addition, the delivery was modified with MLC shifts and jaw position adjustments to compensate for the motion. direction. Figure 5(d) shows the calculated gamma correspondence index 15 with a 2% dose difference criteria and a 2 mm distance to agreement criteria. The dose difference criteria are calculated relative to the maximum planned dose. Neglecting the local discrepancy due to the pin-prick in the film, the gamma passing rate within the 1 Gy contour (50% of the prescription dose) is 98%.
The original planned dose distribution in the acrylic phantom is shown in Fig. 5(e) . Figure 5(f) shows the calculated dose with the 4 mm step motion applied in the IEC-X (lateral) direction, and Fig. 5(g) shows the corresponding film measurements where the same motion profile is applied to the phantom. The step motion occurred approximately 30 s into the 105 s total delivery time. Unlike the longitudinal step motion, the lateral step does not affect the dose in the interior region of the target but rather results in a translation of the delivered dose affecting only the periphery of the target. In both the calculations and film measurements, the superior (positive Y) end of the dose distribution, which was delivered prior to the step motion, can be seen to be better centered around the X = 0 axis. The inferior two-thirds of the dose, instead of being centered around X = 0 as shown in the planned dose distribution of Fig. 5(e) , is offset by 4 mm. Figure 5 (h) shows the gamma correspondence index with a 2%/2 mm criteria. The gamma passing rate within the 1 Gy contour is 99%.
3.B. Adding motion compensation
The original delivery plans of Figs. 5(a) and 5(e) were modified with motion-compensating jaw and MLC adjustments. The resulting dose calculations and measurements are shown in Fig. 6 . Figure 6(a) shows the calculated dose and Fig. 6(b) shows the film measurements in the cheese phantom with longitudinal step motion. With the motion compensation, the dose distribution is uniform and does not exhibit the underdosing that is observed without compensation. Figure 6(c) shows the 2%/2 mm gamma correlation between calculations and film results, with a 95% passing rate within the 1 Gy contour. Figure 6 (d) shows the calculated dose and Fig. 6 (e) shows the film measurements in the acrylic phantom with the 4 mm transverse step motion. Instead of a shift in the negative X direction shown in Figs. 5(f) and 5(g), the dose distribution has a slight shift in the positive X direction. The overcompensation is due to the discretization of the MLC leaves, which have a 6.25 mm width at isocenter. The 2%/2 mm gamma correlation shown in Fig. 6 (f) has a 98% passing rate within the 1 Gy contour.
3.C. Dose profile comparisons
The dose profiles in the acrylic phantom both with, and without, transverse motion are shown in Fig. 7 . The profiles are taken through the origin of the two-dimensional dose planes shown in Figs. 5(e)-5(g) and 6(d)-6(e). In Fig. 7(a) , lateral dose profiles along the Y = 0 axis are displayed.
When a lateral step motion is added without any compensation, the delivered dose (thin line -calculated, dottedfilm) is simply shifted with respect to the original planned dose (thick blue line) by 4 mm corresponding to the 4 mm step motion. When delivery compensation is added, both calculations (gray) and film measurements (dashed) show that the dose distribution is overcompensated by 2 mm due to the discretized leaf width of 6.25 mm.
The longitudinal dose profiles along the X = 0 axis for the same dose distributions are shown in Fig. 7(b) . Since the main impact of the lateral step motion is to shift the delivered dose laterally, the longitudinal dose profiles along the X = 0 axis are unchanged from the original planned dose distribution. Figure 8 shows the longitudinal dose distributions in the cheese phantom for two different longitudinal motion profiles and three different planning field widths. All profiles are through the origin of the dose planes as shown in Figs. 5 and 6. Figures 8(a)-8(c) show the impact of a 4 mm SI (IEC-Y) step motion, where (a) was planned with a 1 cm field width, (b) was planned with a 2.5 cm field width and dynamic-jaw delivery, and (c) was planned with a 5 cm field width and dynamic-jaw delivery. When motion is added approximately halfway through each delivery (thin line -calculated, dotted -film), the superior side (positive Y) of the dose distribution that was delivered prior to the motion is unaffected, while the inferior side (negative Y) is shifted by 4 mm. In between, all areas of the target that were under the beam, or up to 4 mm superior to the beam, are exposed to the beam for a shorter time as the step motion was in the same direction as the couch motion, and therefore that axial region is underdosed. For the 1 cm beam in Fig. 8(a) , the width of the region that is underdosed is approximately 1 cm (full-width at half the maximum impact), and the delivered dose is up to 28% lower than the planned dose. For the 2.5 cm beam in Fig. 8(b) , the width of the underdosed region is approximately 2.5 cm, and the dose discrepancy is 15%. For the 5 cm beam in Fig. 8(c) , the width of the underdosed region is approximately 5 cm, and the dose discrepancy is 7%.
Lastly, the longitudinal dose distribution for the 5 cm field width cheese phantom plan is shown in Fig. 8(d) , but the sinusoidal motion profile shown in Fig. 2(a) is used instead of a step motion. The motion has a peak-to-peak amplitude of 6 mm and an average offset of 3 mm. The motion is introduced immediately and therefore, unlike the previous dose profiles with step motion, the superior edge of the dose is affected as well as the inferior edge. Both edges of the dose with motion are shifted by 3 mm due to the 3 mm average offset in the motion. When motion compensation is included, the calculated dose (gray) and film measurements (dashed) are in good agreement with the originally planned dose (thick blue).
3.D. Dose calculation examples
The dose calculator, validated in previous sections, can be used to study the impact of motion. In Fig. 9 , calculated dose Medical Physics, 45 (1), January 2018 profiles are shown for a variety of longitudinal step motions ranging in size from À10 mm to +10 mm as well as for a sinusoidal motion with a peak-to-peak amplitude of 12 mm and a period of 4 s. The same motion traces, except for adjustments in the timing of the steps to occur midway through each delivery, are used to examine the impact on the 1 cm field width treatment plan [ Fig. 9(a) ], the 2.5 cm field width treatment plan [ Fig. 9(b) ], and the 5.0 cm field width treatment plan [ Fig. 9(c) ]. In Figs. 9(d)-9(f) , motion compensation is added to the delivery plan to accommodate the motion and the dose recalculated. The jaw positions were constrained to the limits allowed by the existing TomoTherapy jaws which can extend approximately 3 mm beyond the 5 cm field width opening. The jaw constraints limit the effectiveness of the compensation for the 5 cm field width as seen in Fig. 9(f) . The impact of transverse (IEC-X) motion on the 2.5 cm field width plan dose is shown in Fig. 10 . The same step motion and sinusoidal motion are reused but oriented in the transverse direction. Unlike previous sections which applied the transverse motion to the acrylic phantom to accommodate experimental limitations, here the transverse motion is applied to the cheese phantom. Figure 10(a) shows the calculated dose without compensation, while Fig. 10(b) shows the dose with MLC compensation. The impact of motion on the 1.0 cm and 5.0 cm field width plans are not shown as they are virtually identical to the results for the 2.5 cm field width.
DISCUSSION
In this study, we have demonstrated the accuracy of the TomoTherapy dose calculator in calculating dose with both simple, nonperiodic motion traces and sinusoidal motion traces. Our results agree with the conclusions in Ref. [10] which used an older version of the TomoTherapy dose calculator and found that motion could be accurately modeled. We have used an updated dose calculator that uses slightly different algorithms to take advantage of the GPU architecture, and which has improved spatial and temporal resolution.
In addition to evaluating the accuracy of the dose calculator, we have explored some simple motion traces that can be useful for understanding the impacts of motion. In Ref. [3] , the authors chose similar step motion profiles for their experimental study of the impact of motion on helical TomoTherapy deliveries. They characterized the dosimetric impact of longitudinal steps of 1 mm to 5 mm in amplitude and using delivery plans with a 1 cm or 2.5 cm field width. For a 4 mm step with a 1 cm field width, they observed a roughly 32% peak difference between the delivered dose and the planned dose, in good agreement with the 29% peak difference we observed and shown in Fig. 9(a) . We attribute the 3% difference between our results to be due to measurement error as well as real differences caused by machine-to-machine variations. With the 2.5 cm field width plan, they found the 4 mm step caused a 14% change to the dose, in close agreement with the calculated results shown in Fig. 9 (b). They show that the dose variation per mm of displacement is about half as much for the 2.5 cm field width plan compared to the 1 cm field with. Our results confirm this and further indicate that with a 5 cm field width plan the trend will continue. As the field width is increased, the impact of longitudinal step motions is distributed over a larger area, thus reducing the relative change in dose at any particular location. Additional types of motion traces will be interesting topics for future investigations. Prostate motions can be approximated as step moves, slow drifts, or brief excursions. Furthermore, if the real-time motion trace can be extracted using a motion monitoring device, the actual clinical motion in three dimensions can be used as input to the dose calculations. Similarly, more realistic respiratory motion traces may be an interesting topic of future investigations. Ultimately, the most realistic patient motion will be nonrigid motion. However, the study of nonrigid motion will add complexity to both the dose calculations and the dose measurements. The rigid motion approximation is likely to be a good approximation for regions close to the tumor (assuming the motion trace represents the tumor motion).
The measurements in this work were performed using film. Compared to most alternative two-dimensional and three-dimensional digital measurement devices, the excellent resolution that film provides was considered to be important for this work. Additionally, the simple motion traces allowed us to focus our measurements in certain directions. However, future investigations with more complex motion may necessitate using three-dimensional measurement devices and full volumetric comparisons to the calculated dose.
In addition to validating the dose calculations with motion, we have also shown the feasibility of a motion compensation method that moves the jaws to follow the SI tumor motion and shifts the MLC leaves to follow the transverse tumor motion. In the case of a treatment plan that uses a 1 cm treatment beam, a 4 mm step motion in the SI direction caused a 28% change to the delivered dose compared to the original planned dose. But including a motion compensation method that shifted the jaws to follow the tumor motion yielded a delivered dose that matched the original planned dose to within 2% and 2 mm.
The method of motion compensation could be further improved. We have neglected higher order corrections such as corrections for the cone fluence profile of the TomoTherapy beam, or inverse-square corrections for the source to target distance. For a target near the isocenter axis with a source-to-axis distance of 85 cm, a 1 cm change in distance would change the fluence by 2.3%. For an off-axis target, the cone fluence profile drops by approximately 2.5% per cm. For example, to compensate for these effects, the leaf open times could be adjusted.
An aspect of motion compensation that we have neglected in this work is the ability to detect the motion. A variety of methods have been used to monitor tumor motion in radiotherapy, including methods using ultrasound, 16 radio-frequency beacons, 17 and x-ray images. 18, 19 Each of these tracking methods has advantages and limitations, and the dose calculator described in this work can be used to help 
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Step 12mm Sin investigate the impact of these limitations on the delivered dose. Limitations in tracking accuracy, for example, can be investigated by introducing compensation errors, and limitations in the sample rate can be modeled by limiting the rate at which the compensation is updated.
CONCLUSION
A primary goal of this work was to evaluate the dose calculation tool and the method of adding arbitrary rigid motion so that others may use the tool to extend this work to more realistic dose distributions, a wider range of clinical delivery plans, and more realistic motion traces. We have shown that for rigid motion with an arbitrary periodic or nonperiodic motion trace, the research version of the clinical TomoTherapy dose calculator accurately calculates a three-dimensional dose volume, including with treatment plans using the TomoEDGE dynamic-jaw delivery feature. Finally, we have shown the feasibility of a motion compensation method that uses the jaws and MLC to track the target motion.
CONFLICTS OF INTEREST
The authors are employees of Accuray Incorporated.
a)
Author to whom correspondence should be addressed. Electronic mail: echao@accuray.com.
